Search

Your search keyword '"Biotechnology industry -- Licensing agreements"' showing total 469 results
Start Over Descriptor "Biotechnology industry -- Licensing agreements" Publisher comtex news network, inc.
469 results on '"Biotechnology industry -- Licensing agreements"'

1. Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets

Subjects
Nufarm Ltd. -- Licensing agreements, Intellectual property, Biotechnology industry -- Licensing agreements, Agricultural chemicals industry -- Licensing agreements, Fatty acids -- Licensing agreements, Oil and gas leases -- Licensing agreements, Intellectual property, Company licensing agreement, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- WEST SACRAMENTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) ('Yield10' or the 'Company'), an agricultural bioscience company, today announced that the [...]

Published
2024

2. Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets

Subjects
Nufarm Ltd. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Agricultural chemicals industry -- Licensing agreements, Fatty acids -- Licensing agreements, Oil and gas leases -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

WEST SACRAMENTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) ('Yield10' or the 'Company'), an agricultural bioscience company, today announced that the Company has signed a Memorandum [...]

Published
2024

3. Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets

Subjects
Nufarm Ltd. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Agricultural chemicals industry -- Licensing agreements, Fatty acids -- Licensing agreements, Oil and gas leases -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

- Nufarm to pay up to USD $5 million in consideration for the license -The parties will negotiate the sale of essentially all of Yield10's assets to Nufarm WOBURN, Mass. [...]

Published
2024

4. Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Subjects
Novavax Inc. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Influenza, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines - Agreement provides patients with broader access to [...]

Published
2024

5. Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Subjects
Novavax Inc. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Influenza, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine [...]

Published
2024

6. MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Subjects
Imugene Ltd. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Immunotherapy, Cancer -- Care and treatment, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

ROCKVILLE, Md., and SYDNEY, Australia, Jan. 23, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=ELIYjWa3dgeNHL15M1eCvJRD13zJxqX8b6-lBZKbm-etFeoHSqitcxP5l0ojgZCxA8QOQFPKbZgVjH3lJXfIBw==, (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development [...]

Published
2024

7. TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision's Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases

Subjects
T cells, Biotechnology, Biotechnology industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), 'the Company,' today https://www.globenewswire.com/Tracker?data=Qc49-grK-96P_feYaRa3jnVgOkYlIajaC75UsqBeQPCTIlX5-xCXedqwG52ei5kdO17uH2LVEFb-tVn8uH5lFDrVoZ783ZPAT2RbBElpodapw9dIEp6WMDEe3UjBJbxso2i3mHf6FIOXArE60OOaNQ== with https://www.globenewswire.com/Tracker?data=Ed3rWC9IM0X9fZmWVogaDmrtIe2WGwpoZp_DgY1T7lvYzmWFC4nBXE7h9kjV9kg_wb1uhibX3RlRI1iD9W7PcirSnmZVceVHa1qcKaeqXT0=, Inc. (https://www.globenewswire.com/Tracker?data=fe--j4woavlQQylGpdT75IRwpKLypU69ECsKwI50hu1omti_scT2KOXGTwOKuzpERdF-wJ_6LApUa3onFSbyhg== GS: DTIL) to acquire a worldwide license to Precision's [...]

Published
2024

8. Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Subjects
Galapagos N.V. -- Licensing agreements, Drug discovery, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

Strategic collaboration and licensing agreement further strengthens Galapagos' growing early-stage pipeline in oncology precision medicine Collaboration leverages Galapagos' expertise in small molecule drug discovery and development with BridGene's innovative discovery [...]

Published
2024

9. Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Subjects
Galapagos N.V. -- Licensing agreements, Drug discovery, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- - Strategic collaboration and licensing agreement further strengthens Galapagos' growing early-stage pipeline in oncology precision medicine - Collaboration leverages Galapagos' expertise in small molecule drug [...]

Published
2024

10. Dare Bioscience Secures $12 million in Royalty-backed Investment Structure

Subjects
Rate of return, Biotechnology industry -- Licensing agreements, Governmental investigations, Return on investment, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced it has entered into a royalty-backed financing agreement that [...]

Published
2023

11. Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

Subjects
Vertex Pharmaceuticals Inc. -- Licensing agreements, Editas Medicine Inc. -- Licensing agreements, Sickle cell anemia, Biotechnology industry -- Licensing agreements, Drugs -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY(TM) (exagamglogene autotemcel) Agreement extends Editas Medicine's cash runway into 2026 CAMBRIDGE, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Editas [...]

Published
2023

12. Sosei Heptares Will Receive US$3.75 Million Payment in Multi-Target Partnership

Subjects
Roche Holding AG -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

Tokyo, Japan and Cambridge, UK, 31 October 2023 - Sosei Group Corporation ('Sosei Heptares' or 'the Company'; TSE: 4565) will receive a US$3.75 million milestone payment under the 2019 multi-target [...]

Published
2023

13. Yield10 Bioscience Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Camelina Technology from Rothamsted Research

Subjects
Biotechnology industry -- Licensing agreements, Fatty acids -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

WOBURN, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ('Yield10' or the 'Company'), an agricultural bioscience company, today announced that the Company has exercised its option to [...]

Published
2023

14. Dare Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO(TM) (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in Females 12 Years or Older

Subjects
Clindamycin -- Licensing agreements, Biotechnology industry -- Licensing agreements, Governmental investigations, Phosphates -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

SAN DIEGO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced the first shipment of XACIATOTM [pronounced zah-she-AH-toe] (clindamycin phosphate) [...]

Published
2023

15. Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair(R) (omalizumab)

Subjects
Omalizumab -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business, Xolair (Medication) -- Licensing agreements
Abstract

REYKJAVIK, Iceland and PISCATAWAY, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide [...]

Published
2023

16. Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience

Subjects
Biopharmaceutics -- Licensing agreements, Biotechnology -- Laws, regulations and rules, Biotechnology industry -- Licensing agreements, Government regulation, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult cancers with high unmet need Collaboration augments Day One's portfolio of targeted [...]

Published
2023

17. Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera

Subjects
Alnylam Pharmaceuticals Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Polycythemia, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

- Preclinical siRNA Targeting TMPRSS6 is a Potential Disease-Modifying Treatment for Polycythemia Vera - - Agreement Combines Agios' Scientific Expertise and Capabilities in Rare Hematologic Diseases with Alnylam's Industry-Leading siRNA [...]

Published
2023

18. Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse(R) in Greater China with Baylor BioSciences

Subjects
Biotechnology industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

WARREN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ('Bellerophon' or the 'Company'), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced [...]

Published
2023

19. CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Subjects
United States. Securities and Exchange Commission, Moderna Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Messenger RNA, Vaccines -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

Collaboration will combine Moderna's mRNA technology with CytomX's Probody[sup.(R)] Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront payment with the potential [...]

Published
2023

20. Dare Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea

Subjects
United States. Food and Drug Administration, Sildenafil, Biotechnology, Biotechnology industry -- Licensing agreements, Contraceptives -- Licensing agreements, Governmental investigations, Anti-inflammatory drugs, Sexual disorders, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Dare Portfolio Accomplishments Include: Two Additional Portfolio Programs (DARE-GML and [...]

Published
2022

21. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015 to 2022

Subjects
Biotechnology -- Reports, Biotechnology industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

New York, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report 'Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015 to 2022' - [...]

Published
2022

22. MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program

Subjects
MaxCyte Inc. -- Licensing agreements, Vertex Pharmaceuticals Inc. -- Licensing agreements, Genes, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

Vertex Pharmaceuticals will continue to use MaxCyte's Flow Electroporation(R) technology and ExPERT(TM) platform to support gene-edited cell therapy exa-cel, formerly known as CTX001(TM) for hemoglobinopathies ROCKVILLE, Md., Sept. 28, 2022 [...]

Published
2022

23. Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK(R) (tisotumab vedotin-tftv)

Subjects
Zai Lab Ltd. -- Licensing agreements, Seagen Inc. -- Licensing agreements, Metastasis, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Viral antibodies, Cervical cancer, Drug approval, Antibodies, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

-- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK, an FDA-approved First-in-Class Antibody-Drug Conjugate (ADC), in Mainland China, Hong Kong, Macau, and Taiwan -- -- Zai Lab will [...]

Published
2022

24. Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab

Subjects
Roche Holding AG -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Monoclonal antibodies, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

HAMILTON, Bermuda, Sep 12, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:KNSA), EQNX::TICKER_END Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate [...]

Published
2022

25. Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab

Subjects
Roche Holding AG -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business, Arcalyst (Medication) -- Licensing agreements
Abstract

HAMILTON, Bermuda, Aug 03, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:KNSA), EQNX::TICKER_END - Kiniksa to receive $100 million in upfront and near-term payments - - Kiniksa is eligible to [...]

Published
2022

26. Kelun-Biotech Announces Oncology Research Collaboration and License Agreement with MSD

Subjects
Merck & Company Inc. -- Licensing agreements, Biological products -- Licensing agreements, Biotechnology, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

CHENGDU, China, Jul 26, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START EQNX::TICKER_END Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), a clinical-stage biotech company focused on biologic and [...]

Published
2022

27. ProPhase Labs Announces Licensing of New Investigational Cancer Compounds

Subjects
Biotechnology industry -- Licensing agreements, Cancer -- Health aspects, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

Garden City, NY, Jul 21, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:PRPH), EQNX::TICKER_END Confirms Quarterly Growth continues year-over-year Announces significant progress being made in Genomics Business Company to Host [...]

Published
2022

28. Dare Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO(TM) (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis

Subjects
Vaginosis, Clindamycin -- Licensing agreements, Biotechnology industry -- Licensing agreements, Health care industry -- Licensing agreements, Drug approval, Phosphates -- Licensing agreements, Health care industry, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

SAN DIEGO, June 30, Jun 30, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:DARE),(NYSE:OGN), EQNX::TICKER_END Dare will receive a $10 million upfront payment from Organon An estimated 21 million American [...]

Published
2022

29. Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer

Subjects
Editas Medicine Inc. -- Licensing agreements, T cells, Genes, Biotechnology industry -- Licensing agreements, Immunotherapy, Drugs -- Licensing agreements, Cancer -- Care and treatment -- Genetic aspects, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

TUEBINGEN, Germany and HOUSTON and CAMBRIDGE, Jun 07, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:EDIT), EQNX::TICKER_END Immatics N.V. (Nasdaq: IMTX, 'Immatics'), a clinical-stage biopharmaceutical company active in the discovery [...]

Published
2022

30. BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines

Subjects
BioNTech SE -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Messenger RNA, Vaccines -- Licensing agreements, Company licensing agreement, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- - Exclusive collaboration combines BioNTech's mRNA vaccine development expertise and Matinas' Lipid Nanocrystal (LNC) Delivery Platform Technology to advance novel formulations for mRNA vaccines, including [...]

Published
2022

31. EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs

Subjects
Biotechnology, Biotechnology industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

BEIJING and CAMBRIDGE, Mass., Feb 08, 2022 (GLOBE NEWSWIRE via COMTEX) -- EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious [...]

Published
2022

32. MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs

Subjects
MaxCyte Inc. -- Licensing agreements, Tumors, Biotechnology, Biotechnology industry -- Licensing agreements, Lymphocytes, Genetic engineering, Genetically modified organisms, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

NEW YORK and GAITHERSBURG, Md., Feb 01, 2022 (GLOBE NEWSWIRE via COMTEX) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell [...]

Published
2022

33. Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR(TM) Technology

Subjects
Allogene Therapeutics Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Genetically modified organisms, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

SOUTH SAN FRANCISCO, Calif. and GENEVA, Jan 11, 2022 (GLOBE NEWSWIRE via COMTEX) -- -- miCAR Platform Enables Simultaneous Silencing of Multiple Gene Targets -- Allogene to Deploy miCAR and [...]

Published
2022

34. Sosei Heptares Announces Antitrust Clearance of License Agreement with Neurocrine Biosciences

Subjects
Neurocrine Biosciences Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

TOKYO, Japan and CAMBRIDGE, United Kingdom, Dec 23, 2021 (GLOBE NEWSWIRE via COMTEX) -- Sosei Group Corporation ('Sosei Heptares'; TSE: 4565) today announces that in connection with the Collaboration and [...]

Published
2021

35. UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of I[+ or -]-Klotho Program

Subjects
Biotechnology, Biotechnology industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

SOUTH SAN FRANCISCO, Calif., Dec 20, 2021 (GLOBE NEWSWIRE via COMTEX) -- UNITY Biotechnology, Inc. ('UNITY') [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of [...]

Published
2021

36. MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs

Subjects
MaxCyte Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Cancer -- Care and treatment, Killer cells, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

SOUTH SAN FRANCISCO and GAITHERSBURG, Md., Oct 28, 2021 (GLOBE NEWSWIRE via COMTEX) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo [...]

Published
2021

37. Selecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene Therapy and Autoimmune Disease

Subjects
Genes, Gene therapy, Biotechnology industry -- Licensing agreements, Immunoglobulin G, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

WATERTOWN, Mass., Oct 21, 2021 (GLOBE NEWSWIRE via COMTEX) -- - Selecta obtains from Genovis exclusive worldwide rights to Xork, a differentiated IgG protease - - Selecta combines ImmTOR(TM) platform [...]

Published
2021

38. Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

Subjects
Communicable diseases, T cells, Biotechnology industry -- Licensing agreements, Cancer -- Care and treatment, Monoclonal antibodies, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

DURHAM, N.C. and NEW YORK and LONDON, Sep 02, 2021 (GLOBE NEWSWIRE via COMTEX) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and [...]

Published
2021

39. Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

Subjects
Communicable diseases, Biotechnology industry -- Licensing agreements, Cancer -- Care and treatment, Monoclonal antibodies, Company licensing agreement, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Precision Gains Access to Tiziana's Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio DURHAM, N.C. and NEW YORK [...]

Published
2021

40. Shape Therapeutics enters into a strategic research collaboration with Roche to advance breakthrough AAV-based RNA editing technology for neuroscience and rare disease indications

Subjects
Roche Holding AG -- Licensing agreements, Biotechnology industry -- Licensing agreements, RNA, Neurosciences, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

SEATTLE, Aug 24, 2021 (GLOBE NEWSWIRE via COMTEX) -- Shape Therapeutics Inc. (Shape), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced a multi-target [...]

Published
2021

41. Orion Corporation and Alligator Bioscience announce immuno-oncology research collaboration and license agreement

Subjects
Alligator Bioscience -- Licensing agreements, Orion Corp. -- Licensing agreements, Industrial equipment and supplies industry -- Licensing agreements, Biotechnology, Viral antibodies, Biotechnology industry -- Licensing agreements, Antibodies, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- ORION CORPORATION PRESS RELEASE 18 AUGUST 2021 at 9.00 a.m. EEST Orion Corporation and Alligator Bioscience announce immuno-oncology research collaboration and license agreement Orion Corporation [...]

Published
2021

42. Athenex Announces Additional Licensing Agreements for Tirbanibulin

Subjects
CSL Ltd. (Parkville, Victoria, Australia) -- Licensing agreements, Biotechnology industry -- Licensing agreements, Cancer -- Care and treatment, Company licensing agreement, Banking, finance and accounting industries, Business, Klisyri (Medication) -- Licensing agreements
Abstract

BUFFALO, Jul 26, 2021 (GLOBE NEWSWIRE via COMTEX) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment [...]

Published
2021

43. Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708

Subjects
Biotechnology industry -- Licensing agreements, Cancer -- Care and treatment, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

SOUTH SAN FRANCISCO, May 17, 2021 (GLOBE NEWSWIRE via COMTEX) -- --CB-708 is an oral small molecule inhibitor of CD73 in preclinical development for oncology --Antengene is granted exclusive rights [...]

Published
2021

44. UPDATE - Advaxis Announces Achievement of Second Milestone Under ADXS-HER2 Licensing Agreement with OS Therapies

Subjects
Advaxis Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Immunotherapy, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

PRINCETON, Apr 26, 2021 (GLOBE NEWSWIRE via COMTEX) -- Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the [...]

Published
2021

45. Advaxis Announces Receipt of Second Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies

Subjects
Advaxis Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Immunotherapy, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

PRINCETON, Apr 26, 2021 (GLOBE NEWSWIRE via COMTEX) -- Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the [...]

Published
2021

46. MatriSys Bioscience Expands Licensing Agreement with UCSD School of Medicine to Develop Acne Treatment

Subjects
Biotechnology industry -- Licensing agreements, Antiacne agents, Medical colleges, Skin, Acne, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

LA JOLLA, Mar 18, 2021 (GLOBE NEWSWIRE via COMTEX) -- MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced that the company has licensed the [...]

Published
2021

47. Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics

Subjects
Microbiota (Symbiotic organisms), Biotechnology industry -- Licensing agreements, Venture capital companies -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

NEW HAVEN, Mar 01, 2021 (GLOBE NEWSWIRE via COMTEX) -- Agreement enables Biohaven to exercise option on up to three of Artizan's candidates for the treatment of inflammatory bowel disease [...]

Published
2021

48. Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent

Subjects
Oncology Pharma Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Chemotherapy, Cancer -- Chemotherapy, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

San Francisco, CA, Feb 26, 2021 (GLOBE NEWSWIRE via COMTEX) -- via NewMediaWire -- Oncology Pharma Inc. (OTC: ONPH) is pleased to announce that it has executed a world-wide Licensing [...]

Published
2021

49. Oncology Pharma Extends Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Veterinary Oncology

Subjects
Oncology Pharma Inc. -- Licensing agreements, Intellectual property, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Intellectual property, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

SAN FRANCISCO, CA, Feb 22, 2021 (GLOBE NEWSWIRE via COMTEX) -- via NewMediaWire -- Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has extended a world-wide Licensing [...]

Published
2021

50. Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea

Subjects
Novavax Inc. -- Licensing agreements, BioScience Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Existing partnership for manufacture of NVX-CoV2373 expanded to increase production capacity and supply vaccine to the Korean Government GAITHERSBURG, Md., Feb. 15, 2021 (GLOBE NEWSWIRE) [...]

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results